Henke D, Renwick A, Zoeller J, Meena J, Neill N, Bowling E
NPJ Precis Oncol. 2025; 9(1):39.
PMID: 39915634
PMC: 11802771.
DOI: 10.1038/s41698-025-00825-9.
Ibrahim S, Khan M, Khurram I, Rehman R, Rauf A, Ahmad Z
Food Sci Nutr. 2025; 13(2):e70011.
PMID: 39898116
PMC: 11786021.
DOI: 10.1002/fsn3.70011.
Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T
J Biol Chem. 2024; 300(12):107994.
PMID: 39547513
PMC: 11714729.
DOI: 10.1016/j.jbc.2024.107994.
Gonzalez-Martinez D, Roth L, Mumford T, Guan J, Le A, Doebele R
Nat Commun. 2024; 15(1):9473.
PMID: 39488530
PMC: 11531495.
DOI: 10.1038/s41467-024-53451-7.
Yi M, Soppet D, McCormick F, Nissley D
Sci Rep. 2024; 14(1):25452.
PMID: 39455841
PMC: 11511894.
DOI: 10.1038/s41598-024-76591-8.
Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors.
Lazar V, Raymond E, Magidi S, Bresson C, Wunder F, Berindan-Neagoe I
Ther Adv Med Oncol. 2024; 16:17588359241289200.
PMID: 39429467
PMC: 11487509.
DOI: 10.1177/17588359241289200.
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A
Signal Transduct Target Ther. 2024; 9(1):201.
PMID: 39138146
PMC: 11323831.
DOI: 10.1038/s41392-024-01899-w.
Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver mutations.
Besedina E, Supek F
Nat Commun. 2024; 15(1):6139.
PMID: 39033140
PMC: 11271286.
DOI: 10.1038/s41467-024-50552-1.
Canonical and Noncanonical Functions of the BH3 Domain Protein Bid in Apoptosis, Oncogenesis, Cancer Therapeutics, and Aging.
Makinwa Y, Luo Y, Musich P, Zou Y
Cancers (Basel). 2024; 16(12).
PMID: 38927905
PMC: 11202167.
DOI: 10.3390/cancers16122199.
DUSP1 Promotes Osimertinib Drug-Tolerant Persistence by Inhibiting MAPK/ERK Signaling in Non-small Cell Lung Cancer.
He W, Liu P, Lei Q, Xu J, Liu L
Mol Biotechnol. 2024; 67(3):1256-1268.
PMID: 38551790
DOI: 10.1007/s12033-024-01127-4.
Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc.
Williams J, Higgins A, Stott K, Thomas C, Farrell L, Bonnet C
Cell Biosci. 2024; 14(1):38.
PMID: 38521952
PMC: 10961001.
DOI: 10.1186/s13578-024-01206-8.
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework.
Timofeev O, Giron P, Lawo S, Pichler M, Noeparast M
NPJ Precis Oncol. 2024; 8(1):70.
PMID: 38485987
PMC: 10940698.
DOI: 10.1038/s41698-024-00554-5.
Theranostic Fluorescent Probes.
Sharma A, Verwilst P, Li M, Ma D, Singh N, Yoo J
Chem Rev. 2024; 124(5):2699-2804.
PMID: 38422393
PMC: 11132561.
DOI: 10.1021/acs.chemrev.3c00778.
The ESCRT protein CHMP5 promotes T cell leukemia by controlling BRD4-p300-dependent transcription.
Umphred-Wilson K, Ratnayake S, Tang Q, Wang R, Devaiah B, Zhou L
bioRxiv. 2024; .
PMID: 38352301
PMC: 10862731.
DOI: 10.1101/2024.01.29.577409.
Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E, Chun K, Kim D
Int J Mol Sci. 2024; 25(3).
PMID: 38338729
PMC: 10855972.
DOI: 10.3390/ijms25031450.
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer.
Rutherford K, McManus K
Mol Cancer Ther. 2024; 23(4):454-463.
PMID: 38205881
PMC: 10985480.
DOI: 10.1158/1535-7163.MCT-23-0747.
The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells.
Chapdelaine A, Ku G, Sun G, Ayrapetov M
Cancers (Basel). 2023; 15(24).
PMID: 38136350
PMC: 10741866.
DOI: 10.3390/cancers15245805.
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
Lap C, Abrahim M, Nassereddine S
Ann Hematol. 2023; 103(7):2215-2229.
PMID: 37975931
DOI: 10.1007/s00277-023-05545-3.
ORAOV1, CCND1, and MIR548K Are the Driver Oncogenes of the 11q13 Amplicon in Squamous Cell Carcinoma.
Mahieu C, Mancini A, Vikram E, Planells-Palop V, Joseph N, Tward A
Mol Cancer Res. 2023; 22(2):152-168.
PMID: 37930255
PMC: 10831340.
DOI: 10.1158/1541-7786.MCR-23-0746.
Urinary Metabolic Distinction of Niemann-Pick Class 1 Disease through the Use of Subgroup Discovery.
Carmona C, German-Morales M, Elizondo D, Ruiz-Rodado V, Grootveld M
Metabolites. 2023; 13(10).
PMID: 37887404
PMC: 10608721.
DOI: 10.3390/metabo13101079.
